Tetra Bio-Pharma Inc. is pleased to announce that all matters presented for approval at the Corporation’s annual general and special meeting of shareholders of the Corporation held in Montréal, province of Québec, on June 20, 2019, were approved.
Tetra Bio-Pharma Inc. is pleased to announce that it has filed and received a receipt for a preliminary short form prospectus in connection with a proposed offering of units for minimum gross proceeds of C$3,500,000 and maximum gross proceeds of C$7,000,000.
Tetra Bio-Pharma Inc. is pleased to provide investors with an update on our research, regulatory and commercial activities. This market update covers Tetra and its subsidiaries, Panag and Tetra Natural Health (TNH).
Carol Levine (Energi PR)
Tel: 514.288.8500, ext. 226